Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
4.610
-1.255 (-21.40%)
Aug 3, 2026, 2:12 PM EDT - Market open
Lexaria Bioscience Balance Sheet
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Cash & Equivalents | 3.48 | 1.8 | 6.5 | 1.35 | 5.81 | 10.92 |
Short-Term Investments | 0.14 | 0.17 | 0.05 | 0.12 | 0.35 | 0.83 |
Cash & Short-Term Investments | 3.62 | 1.97 | 6.55 | 1.48 | 6.16 | 11.75 |
Cash Growth | -21.80% | -69.98% | 344.09% | -76.05% | -47.58% | 794.97% |
Accounts Receivable | 0.05 | 0.37 | 0.15 | 0.19 | 0.2 | 0.34 |
Inventory | - | - | - | - | 0.04 | 0.03 |
Other Current Assets | - | 1.13 | 1.19 | 0.55 | 0.58 | 0.32 |
Total Current Assets | 4.06 | 3.47 | 7.9 | 2.15 | 6.98 | 12.44 |
Net Property, Plant & Equipment | 0.31 | 0.33 | 0.39 | 1.35 | 0.37 | 0.46 |
Other Intangible Assets | 0.34 | 0.31 | 0.52 | 0.46 | 0.49 | 0.36 |
Other Long-Term Assets | 0.78 | 0.77 | 1.03 | 0.05 | 0.86 | 0.82 |
Total Assets | 4.78 | 4.18 | 8.87 | 3.08 | 7.83 | 13.27 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Accounts Payable | 0.35 | 1.46 | 1.07 | 0.24 | 0.15 | 0.11 |
Short-Term Debt | - | - | - | - | - | 0.01 |
Current Portion of Leases | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 |
Unearned Revenue | - | - | 0 | - | - | - |
Total Current Liabilities | 0.38 | 1.49 | 1.1 | 0.27 | 0.19 | 0.15 |
Long-Term Leases | 0.05 | 0.08 | 0.11 | 0.14 | 0.01 | 0.05 |
Total Long-Term Liabilities | 0.05 | 0.08 | 0.11 | 0.14 | 0.01 | 0.05 |
Total Liabilities | 0.44 | 1.57 | 1.21 | 0.4 | 0.2 | 0.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 73.26 | 66.5 | 59.6 | 48.8 | 47.04 | 45.09 |
Accumulated Other Comprehensive Income | -0.05 | -0.07 | -0.02 | - | - | - |
Retained Earnings | -68.5 | -63.46 | -51.56 | -45.76 | -39.1 | -31.83 |
Total Common Shareholders' Equity | 4.74 | 2.99 | 8.04 | 3.04 | 7.95 | 13.27 |
Minority Interest | -0.39 | -0.39 | -0.38 | -0.36 | -0.32 | -0.2 |
Shareholders' Equity | 4.34 | 2.6 | 7.66 | 2.68 | 7.63 | 13.06 |
Total Liabilities & Equity | 4.78 | 4.18 | 8.87 | 3.08 | 7.83 | 13.27 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Total Debt | 0.09 | 0.11 | 0.14 | 0.16 | 0.05 | 0.1 |
Net Cash (Debt) | 3.53 | 1.86 | 6.42 | 1.31 | 6.11 | 11.65 |
Net Cash Growth | -21.70% | -71.04% | 389.13% | -78.53% | -47.57% | 907.32% |
Net Cash Per Share | 0.16 | 0.10 | 0.52 | 0.20 | 1.04 | 2.65 |
Book Value | 4.74 | 2.99 | 8.04 | 3.04 | 7.95 | 13.27 |
Book Value Per Share | 0.21 | 0.17 | 0.65 | 0.46 | 1.35 | 3.02 |
Tangible Book Value | 4.4 | 2.68 | 7.52 | 2.58 | 7.46 | 12.9 |
Tangible Book Value Per Share | 0.20 | 0.15 | 0.61 | 0.39 | 1.27 | 2.94 |